Adverse drug reactions (ADRs) are responsible for ~5% of hospital admissions, and occur during 6-15% of hospital stays. Approximately 30% are caused by drugs with a known major clinically significant pharmacogenomics variant, as much as 30% of adverse drug-related admissions may be predictable – and thus preventable - by pharmacogenomics (PGx) testing.

In this talk, we will discuss the introduction of pharamacogenomics testing into particular clinical settings where it is likely to be particularly clinically relevant. Our project’s goal is to provide pre-emptive rather than reactive testing in these clinical settings by using rapid genomic technologies and information management integrated into the hospital electronic medical record. This vision requires development of a PGx knowledge centre and a clinical support database as well as the validation of new technologies to improve cost effective PGx measurements.

This talk will focus on implementation of these goals as well as the challenges of introducing new genomic testing into routine clinical care.

Associate Professor Paul Leo Principal Research Fellow, Bioinformatics, QUT and Deputy Director, Australian Translational Genomics Center (ATGC), Queensland

A/Prof. Paul Leo is Principal Research Fellow (Bioinformatics) at the Queensland University of Technology.(QUT) and deputy director of the Australian Translational Genomics Center (ATGC). ATGC is a collaboration between QUT and the Princess Alexandria Hospital in Brisbane Australia and provides personalized genomic reports to inform patient management. Part of this initiative is mainstreaming pharmacogenomics testing in Queensland by fostering collaboration with industry partners.